Kiniksa Pharmaceuticals, Ltd.
KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatoā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$45.75
Price-2.20%
-$1.03
1Y
Price
Market Cap
$3.395b
Mid
Price/Earnings 3y Avg5y Avg
61x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+11.7%
EBITDA Margin+7.0%
Net Profit Margin+26.4%
Free Cash Flow Margin+11.7%
EBITDA Margin+7.0%
Net Profit Margin+26.4%
Free Cash Flow MarginRevenue
$677.564m
+60.1%
1y CAGR+46.5%
3y CAGR+152.7%
5y CAGREarnings
$59.005m
+236.6%
1y CAGR-87.5%
3y CAGR-11.6%
5y CAGREPS
$0.75
+225.0%
1y CAGR-89.1%
3y CAGR-13.6%
5y CAGRBook Value
$567.606m
$763.633m
Assets$196.027m
Liabilities$9.497m
DebtDebt to Assets
1.2%
0.1x
Debt to EBITDAFree Cash Flow
$25.412m
+436.8%
1y CAGR+220.3%
3y CAGR+191.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company